BioSpace News Archive

Orthofix Medical Inc., a global medical device company with a spine and orthopedics focus, announced the U.S. launch and first patient implant of the FORZA™ Ti PLIF Spacer System.

Mosaic ImmunoEngineering Inc., a development-stage biotechnology company focused on immunotherapies to treat and prevent cancer and infectious diseases through innate and adaptive immune activation, announced a new preclinical publication available online in the journal Biomaterials that further expand the understanding of the antitumor potency and mechanism of action of the Company’s lead immuno-oncology candidate, MIE-101, a novel Toll-like receptor tri-agonist.

vTv Therapeutics Inc. today announced that it will be presenting data from the clinical development of HPP737 as a treatment for psoriasis in a poster presentation at the 6th World Psoriasis & Psoriatic Arthritis Conference held virtually June 30 – July 3, 2021 in Stockholm, Sweden.

Palatin and FDA Reach Agreement on Path to NDA Submission, including Trial Design, Endpoints, Interim Assessment, and Patient Population

Takeda Pharmaceutical Company Limited today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the “Annual Report”) with the U.S. Securities and Exchange Commission (the “SEC”).

Elicio Therapeutics today announced the initiation of AMPLIFY-201, a Phase 1/2 dose-escalation study evaluating the safety and preliminary efficacy of ELI-002.

HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, announced the appointment of Mark J. Mulvihill, Ph.D., as Chief Scientific Officer, who brings more than 20 years of experience in drug discovery and development with a focus on small molecule therapies.

Reneo Pharmaceuticals, Inc. joined the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the close of the markets on June 28, 2021.

Paratek Pharmaceuticals, Inc. today announced Paratek has delivered the first procurement of NUZYRA to the Biomedical Advanced Research and Development Authority (BARDA).

H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company focused on the field of regenerative medicine, today announced the publication of its clinical observational study titled, “Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy.”